Who Paid My Doc
Jeffrey Chambers
Cardiovascular Disease Minneapolis, MN Medical Doctor
NPI 1437192598 CMS profile 200650
4040 Coon Rapids Blvd Nw, Suite 120, Minneapolis, MN 55433
General payments
$3,224,243
Research payments
$17,673
Ownership & investment interest
$25,000
Research they led as principal investigator
$386,278
Through program year 2025, Jeffrey Chambers of Minneapolis, MN is reported in the CMS Open Payments database as having received $3,224,243 across 535 general payments and $17,673 in research payments paid to them. Separately, studies naming them as principal investigator received $386,278 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $25,000 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $662,711 | 62 | |
| 2025 | Research | $13 | 1 | |
| 2024 | General | $550,892 | 64 | |
| 2024 | Research | $360 | 1 | |
| 2023 | General | $459,974 | 47 | |
| 2022 | General | $399,405 | 70 | |
| 2021 | General | $421,024 | 81 | |
| 2021 | Research | $10,100 | 3 | |
| 2020 | General | $358,265 | 76 | |
| 2020 | Research | $4,200 | 3 | |
| 2019 | General | $371,972 | 135 | |
| 2019 | Research | $3,000 | 2 | |
| 2025 | Ownership | $25,000 | 1 |
Beside peers
- Jeffrey Chambers
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Jeffrey Chambers were reported at $662,711. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Jeffrey Chambers | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $371,972 | $450 | $127–$1,392 | $163 |
| 2020 | $358,265 | $242 | $77–$751 | $114 |
| 2021 | $421,024 | $335 | $101–$1,037 | $132 |
| 2022 | $399,405 | $395 | $121–$1,211 | $149 |
| 2023 | $459,974 | $443 | $136–$1,283 | $160 |
| 2024 | $550,892 | $450 | $136–$1,323 | $164 |
| 2025 | $662,711 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
2,192
Drug cost
$234,038
Branded share of claims
22%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 111 | $123,114 | |
| Jardiance Empagliflozin | Brand | 28 | $45,488 | |
| Entresto Sacubitril/Valsartan | Brand | 23 | $34,366 | |
| Rosuvastatin Calcium | Generic | 283 | $4,369 | |
| Metoprolol Succinate | Generic | 228 | $3,712 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 189 | $2,467 | |
| Atorvastatin Calcium | Generic | 124 | $2,266 | |
| Bumetanide | Generic | 37 | $1,961 | |
| Losartan Potassium | Generic | 140 | $1,843 | |
| Amlodipine Besylate | Generic | 155 | $1,586 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 58 billing codesPaid by Medicare
$114,093
Medicare patients
392
Services billed
866
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Ischemic heart disease | 60% | |
| Atrial fibrillation | 46% | |
| Heart failure | 42% | |
| Chronic kidney disease | 38% | |
| Arthritis | 36% | |
| Diabetes | 35% | |
| Depression | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
545 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Minnesota
Srijoy Mahapatra
Cardiovascular Disease · Rochester, MN
Markus Meyer
Cardiovascular Disease · Minneapolis, MN
Robert Schwartz
Cardiovascular Disease · Minneapolis, MN
Robert Vantassel
Cardiovascular Disease · Minneapolis, MN
Charanjit Rihal
Cardiovascular Disease · Rochester, MN
Amir Lerman
Cardiovascular Disease · Rochester, MN
Related records
Cardiovascular Disease in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.